Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRIPT-TB: Short Course Rifapentine and Isoniazid for TB Prevention
NCT03900858Unknown
- Sponsor
- Huashan Hospital
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of rifapentine and isoniazid in Tuberculosis (TB) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Cumulative rate of culture-confirmed or clinically diagnosed TB disease at 3 years. Status: unknown.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03900858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900858.